IL250391B - Crystalline forms of glutaminase inhibitors - Google Patents
Crystalline forms of glutaminase inhibitorsInfo
- Publication number
- IL250391B IL250391B IL250391A IL25039117A IL250391B IL 250391 B IL250391 B IL 250391B IL 250391 A IL250391 A IL 250391A IL 25039117 A IL25039117 A IL 25039117A IL 250391 B IL250391 B IL 250391B
- Authority
- IL
- Israel
- Prior art keywords
- crystal forms
- glutaminase inhibitors
- glutaminase
- inhibitors
- crystal
- Prior art date
Links
- 102000009127 Glutaminase Human genes 0.000 title 1
- 108010073324 Glutaminase Proteins 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462034547P | 2014-08-07 | 2014-08-07 | |
| PCT/US2015/044301 WO2016022969A1 (en) | 2014-08-07 | 2015-08-07 | Crystal forms of glutaminase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL250391A0 IL250391A0 (en) | 2017-03-30 |
| IL250391B true IL250391B (en) | 2021-10-31 |
Family
ID=55264662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL250391A IL250391B (en) | 2014-08-07 | 2017-02-01 | Crystalline forms of glutaminase inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10316030B2 (enExample) |
| EP (1) | EP3193876B1 (enExample) |
| JP (3) | JP6889101B2 (enExample) |
| KR (1) | KR20170082494A (enExample) |
| CN (1) | CN106999490A (enExample) |
| AU (2) | AU2015300825B2 (enExample) |
| BR (1) | BR112017002403A2 (enExample) |
| CA (1) | CA2957225A1 (enExample) |
| EA (1) | EA037738B1 (enExample) |
| IL (1) | IL250391B (enExample) |
| MX (1) | MX2017001620A (enExample) |
| SG (1) | SG11201700816YA (enExample) |
| WO (1) | WO2016022969A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105017212A (zh) | 2006-09-26 | 2015-11-04 | 细胞基因公司 | 作为抗肿瘤剂的5-取代的喹唑酮衍生物 |
| MX2013010360A (es) | 2011-03-11 | 2014-04-14 | Celgene Corp | Formas solidas sde 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-pi peridin-2,6-diona, y sus composiciones farmaceuticas y usos. |
| US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| ES2814952T3 (es) | 2012-09-04 | 2021-03-29 | Celgene Corp | Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos |
| SMT202100589T1 (it) | 2012-11-16 | 2021-11-12 | Calithera Biosciences Inc | Inibitori di glutaminasi eterociclici |
| SG11201610333VA (en) | 2014-06-13 | 2017-01-27 | Calithera Biosciences Inc | Combination therapy with glutaminase inhibitors |
| EP3193876B1 (en) | 2014-08-07 | 2022-01-12 | Calithera Biosciences Inc. | Crystal forms of glutaminase inhibitors |
| US20160287564A1 (en) * | 2015-03-30 | 2016-10-06 | Calithera Biosciences, Inc. | Methods of administering glutaminase inhibitors |
| JP6944377B2 (ja) | 2015-04-06 | 2021-10-06 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | グルタミナーゼの阻害剤を用いる肺がんの処置 |
| CA3000996A1 (en) | 2015-10-05 | 2017-04-13 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors and immuno-oncology agents |
| JP2019524852A (ja) | 2016-08-25 | 2019-09-05 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | グルタミナーゼ阻害剤を用いる併用療法 |
| SG11201901389XA (en) | 2016-08-25 | 2019-03-28 | Calithera Biosciences Inc | Combination therapy with glutaminase inhibitors |
| US20210177880A1 (en) * | 2017-10-31 | 2021-06-17 | President And Fellows Of Harvard College | Methods and compositions for treating acute myeloid leukemia |
| EP3946601A1 (en) * | 2019-03-26 | 2022-02-09 | Tonix Pharma Holdings Limited | Salt forms of s-(n, n-diethylcarbamoyl)glutathione |
| CN114295836B (zh) * | 2021-12-22 | 2024-12-31 | 融智生物科技（青岛）有限公司 | 一种计算设备、存储介质和胶质瘤idh分型检测装置及系统 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014078645A1 (en) * | 2012-11-16 | 2014-05-22 | Calithera Biosciences, Inc. | Heterocyclic glutaminase inhibitors |
| WO2014089048A1 (en) * | 2012-12-03 | 2014-06-12 | Calithera Biosciences, Inc. | Treatment of cancer with heterocyclic inhibitors of glutaminase |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1019519A (en) | 1911-07-11 | 1912-03-05 | Oscar Martin Polin | Apparatus for making backing for teeth. |
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| US6403609B1 (en) | 1997-07-29 | 2002-06-11 | Alcon Manufacturing, Ltd. | Ophthalmic compositions containing galactomannan polymers and borate |
| US5955476A (en) | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
| CA2318920A1 (en) | 1998-01-29 | 1999-08-05 | James W. Young | Pharmaceutical uses of optically pure (-)-bupropion |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| US6451828B1 (en) | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
| US20040198716A1 (en) | 2001-02-05 | 2004-10-07 | Dorit Arad | Cysteine protease inhimbitors |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| ES2593113T3 (es) | 2003-08-07 | 2016-12-05 | Allergan, Inc. | Composiciones para el suministro de agentes terapéuticos en los ojos y métodos para obtener y usar los mismos |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| US7456027B2 (en) | 2004-04-15 | 2008-11-25 | University Of Florida Research Foundation, Inc. | Proteolytic biomarkers for traumatic injury to the nervous system |
| CL2007002670A1 (es) | 2006-09-15 | 2008-05-16 | Celgene Corp Soc Organizada Ba | Compuestos derivados de n-metilaminometil-isoindolina; composicion farmaceutica; forma de dosificacion, util para tratar o prevenir enfermedades tales como cancer, dolor, trastorno pulmonar, trastorno del snc y aterosclerosis. |
| EP2183232B1 (en) | 2007-08-02 | 2013-03-06 | Amgen, Inc | Pi3 kinase modulators and methods of use |
| US8778410B2 (en) | 2008-02-19 | 2014-07-15 | Earnest Medicine Co., Ltd. | Oral or enteral composition useful for recovery of physical functions |
| WO2010093434A1 (en) | 2009-02-11 | 2010-08-19 | Celgene Corporation | Isotopologues of lenalidomide |
| WO2010093605A1 (en) | 2009-02-11 | 2010-08-19 | Celgene Corporation | Isotopologues of thalidomide |
| ES2730763T3 (es) | 2010-02-11 | 2019-11-12 | Celgene Corp | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos de uso de los mismos |
| US20130109643A1 (en) | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| US10064885B2 (en) | 2010-07-09 | 2018-09-04 | Massachusetts Institute Of Technology | Metabolic gene, enzyme, and flux targets for cancer therapy |
| AU2011329619A1 (en) | 2010-11-18 | 2013-05-02 | Deuteria Pharmaceuticals, Inc. | 3-deutero-pomalidomide |
| WO2012097116A2 (en) | 2011-01-14 | 2012-07-19 | Celgene Corporation | Isotopologues of isoindole derivatives |
| CA2742342A1 (en) | 2011-02-12 | 2012-08-12 | Baylor Research Institute | Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs |
| FI20115876A0 (fi) | 2011-09-06 | 2011-09-06 | Turun Yliopisto | Yhdistelmähoito |
| JP5712882B2 (ja) * | 2011-09-28 | 2015-05-07 | 株式会社豊田自動織機 | 電動圧縮機用の電動モータ |
| CN103030597B (zh) | 2011-09-30 | 2014-10-01 | 南昌滨西科技有限公司 | 肾脏型谷氨酰胺酶抑制剂及其制备方法和用途 |
| US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| CN104220070B (zh) * | 2011-11-21 | 2020-01-21 | 卡利泰拉生物科技公司 | 谷氨酰胺酶的杂环抑制剂 |
| CA2874521A1 (en) | 2012-05-24 | 2013-11-28 | Dana-Farber Cancer Institute, Inc. | Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer |
| CN104797256A (zh) | 2012-09-10 | 2015-07-22 | 细胞基因公司 | 用于治疗局部晚期乳腺癌的方法 |
| EP2895623B1 (en) | 2012-09-17 | 2018-08-22 | Agios Pharmaceuticals, Inc. | Use of e-cadherin and vimentin for selection of treatment responsive patients |
| US10011574B2 (en) | 2012-11-21 | 2018-07-03 | Agios Pharmaceuticals, Inc. | Glutaminase inhibitors and method of use |
| WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| WO2015061432A1 (en) | 2013-10-25 | 2015-04-30 | Calithera Biosciences, Inc. | Treatment of viral infections with inhibitors of glutaminase |
| EP3116872A4 (en) | 2014-03-14 | 2017-08-30 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| US10221459B2 (en) | 2014-05-13 | 2019-03-05 | Case Western Reserve University | Compositions and methods of treating cancer harboring PIKC3A mutations |
| SG11201610333VA (en) | 2014-06-13 | 2017-01-27 | Calithera Biosciences Inc | Combination therapy with glutaminase inhibitors |
| WO2016004418A1 (en) | 2014-07-03 | 2016-01-07 | Board Of Regents, University Of Texas System | Glutaminase inhibitor therapy |
| WO2016014890A1 (en) | 2014-07-24 | 2016-01-28 | Calithera Biosciences, Inc. | Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase |
| EP3193876B1 (en) | 2014-08-07 | 2022-01-12 | Calithera Biosciences Inc. | Crystal forms of glutaminase inhibitors |
| US10245254B2 (en) | 2014-10-03 | 2019-04-02 | University of Pittsburgh—of the Commonwealth System of Higher Education | Glutaminase inhibitors |
| WO2016077632A2 (en) | 2014-11-13 | 2016-05-19 | Buck Institute For Research On Aging | Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications |
| US20160287564A1 (en) | 2015-03-30 | 2016-10-06 | Calithera Biosciences, Inc. | Methods of administering glutaminase inhibitors |
| JP6944377B2 (ja) | 2015-04-06 | 2021-10-06 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | グルタミナーゼの阻害剤を用いる肺がんの処置 |
| CA3000996A1 (en) | 2015-10-05 | 2017-04-13 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors and immuno-oncology agents |
| SG11201901389XA (en) | 2016-08-25 | 2019-03-28 | Calithera Biosciences Inc | Combination therapy with glutaminase inhibitors |
| WO2018039442A1 (en) | 2016-08-25 | 2018-03-01 | Calithera Biosciences, Inc. | Treatment of cancer with inhibitors of glutaminase |
| JP2019524852A (ja) | 2016-08-25 | 2019-09-05 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | グルタミナーゼ阻害剤を用いる併用療法 |
| EP3592354A4 (en) | 2017-03-10 | 2021-04-07 | Calithera Biosciences, Inc. | COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS |
-
2015
- 2015-08-07 EP EP15830024.4A patent/EP3193876B1/en not_active Not-in-force
- 2015-08-07 CA CA2957225A patent/CA2957225A1/en not_active Abandoned
- 2015-08-07 KR KR1020177006199A patent/KR20170082494A/ko not_active Ceased
- 2015-08-07 EA EA201790337A patent/EA037738B1/ru not_active IP Right Cessation
- 2015-08-07 SG SG11201700816YA patent/SG11201700816YA/en unknown
- 2015-08-07 WO PCT/US2015/044301 patent/WO2016022969A1/en not_active Ceased
- 2015-08-07 CN CN201580054339.2A patent/CN106999490A/zh active Pending
- 2015-08-07 BR BR112017002403A patent/BR112017002403A2/pt not_active Application Discontinuation
- 2015-08-07 US US15/501,622 patent/US10316030B2/en not_active Expired - Fee Related
- 2015-08-07 MX MX2017001620A patent/MX2017001620A/es unknown
- 2015-08-07 AU AU2015300825A patent/AU2015300825B2/en not_active Ceased
- 2015-08-07 JP JP2017506401A patent/JP6889101B2/ja not_active Expired - Fee Related
-
2017
- 2017-02-01 IL IL250391A patent/IL250391B/en unknown
-
2019
- 2019-06-07 US US16/434,872 patent/US10676472B2/en not_active Expired - Fee Related
- 2019-11-18 JP JP2019208032A patent/JP2020037588A/ja active Pending
- 2019-12-31 AU AU2019284149A patent/AU2019284149A1/en not_active Abandoned
-
2021
- 2021-06-30 JP JP2021108805A patent/JP2021165286A/ja not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014078645A1 (en) * | 2012-11-16 | 2014-05-22 | Calithera Biosciences, Inc. | Heterocyclic glutaminase inhibitors |
| WO2014089048A1 (en) * | 2012-12-03 | 2014-06-12 | Calithera Biosciences, Inc. | Treatment of cancer with heterocyclic inhibitors of glutaminase |
Non-Patent Citations (1)
| Title |
|---|
| HAYNES, DELIA A., WILLIAM JONES, AND WD SAMUEL MOTHERWELL., OCCURRENCE OF PHARMACEUTICALLY ACCEPTABLE ANIONS AND CATIONS IN THE CAMBRIDGE STRUCTURAL DATABASE., 31 October 2005 (2005-10-31) * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3193876A4 (en) | 2017-12-27 |
| WO2016022969A1 (en) | 2016-02-11 |
| US10676472B2 (en) | 2020-06-09 |
| CN106999490A (zh) | 2017-08-01 |
| US10316030B2 (en) | 2019-06-11 |
| IL250391A0 (en) | 2017-03-30 |
| JP2017523991A (ja) | 2017-08-24 |
| SG11201700816YA (en) | 2017-02-27 |
| JP6889101B2 (ja) | 2021-06-18 |
| AU2015300825B2 (en) | 2019-10-10 |
| EA037738B1 (ru) | 2021-05-17 |
| EP3193876B1 (en) | 2022-01-12 |
| CA2957225A1 (en) | 2016-02-11 |
| AU2019284149A1 (en) | 2020-01-30 |
| BR112017002403A2 (pt) | 2017-12-05 |
| JP2021165286A (ja) | 2021-10-14 |
| MX2017001620A (es) | 2017-05-10 |
| EA201790337A1 (ru) | 2017-09-29 |
| US20170226101A1 (en) | 2017-08-10 |
| AU2015300825A1 (en) | 2017-03-09 |
| JP2020037588A (ja) | 2020-03-12 |
| US20190359607A1 (en) | 2019-11-28 |
| KR20170082494A (ko) | 2017-07-14 |
| EP3193876A1 (en) | 2017-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201604272B (en) | Inhibitors of glutaminase | |
| IL250391B (en) | Crystalline forms of glutaminase inhibitors | |
| IL251584B (en) | Dihydropyrrolopyridines ror–gamma inhibitors | |
| IL246902A0 (en) | Dihydropyrrolopyridine ror–gamma inhibitors | |
| GB2542881B (en) | Crystal forms of ß-nicotinamide mononucleotide | |
| ZA201801417B (en) | Salts of an lsd1 inhibitor | |
| IL249476A0 (en) | Combined treatment with glutaminase inhibitors | |
| IL250046B (en) | Spirocycloheptanes as rock inhibitors | |
| SG11201708034SA (en) | Methods of administering glutaminase inhibitors | |
| GB201521059D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL273463A (en) | Crystalline forms of immunomodulators | |
| GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL253018A0 (en) | Crystalline forms of apomorphine and their uses | |
| GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
| EP3212611A4 (en) | Crystal forms of verapamil hydrochloride | |
| EP3164195A4 (en) | Glutaminase inhibitor therapy | |
| HK1228907A1 (en) | Novel inhibitors of glutaminase | |
| HK1228906A1 (en) | Novel glutaminase inhibitors | |
| GB201421812D0 (en) | New therapeutic uses of enzyme inhibitors | |
| GB201410529D0 (en) | New therapeutic uses of enzyme inhibitors |